Actively Recruiting
Phase II Study of CyberKnife Radiosurgery for Treating Localized Renal Cell Carcinoma
Led by Beth Israel Deaconess Medical Center · Updated on 2024-08-15
46
Participants Needed
1
Research Sites
8 weeks
Total Duration
AI-Summary
What this Trial Is About
Researchers are evaluating the use of CyberKnife Radiosurgery to treat clinically localized primary renal cell carcinoma, a type of kidney cancer. This technology delivers high doses of radiation very precisely to the tumor while minimizing exposure to nearby organs. The study aims to understand how well this treatment controls tumor growth and its effects on patients, focusing on those with early-stage kidney cancer Stage I. Participants will receive CyberKnife Radiosurgery, with the radiation dose adjusted according to tumor size. Treatment typically occurs over 3 to 4 days, but can extend up to 14 days. Before treatment, gold fiducials small markers are placed near the tumor to guide the radiation. During treatment, participants will be positioned carefully using devices like vacuum bags or rigid pillows to keep still and comfortable. Before starting, participants undergo tests such as imaging scans CT, MRI, PET, blood and urine tests, a medical history review, and quality of life surveys. After treatment, researchers will monitor participants long-term, including annual phone calls to check health status. The main outcome is to measure freedom from tumor growth at 6 months and up to 2 years, along with quality of life and any side effects over 2 years.
CONDITIONS
Brief Title
A Phase II Study of Cyberknife Radiosurgery for Renal Cell Carcinoma
Research Team
I
Irving D Kaplan, MD
K
Kaitlyn Scott-Haughey, M.Ed
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
